Jakavi® (ruxolitinib) approved by the European Commission for adult patients with polycythemia vera (PV) resistant to or intolerant of hydroxyurea…
In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional…